⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073309 | 0.85 | — | — | |
| SCHEMBL1644155 | 0.82 | PRMT3 (0.32) | — | |
| SCHEMBL22944191 | 0.82 | PAOX (0.33) | — | |
| SCHEMBL11986884 | 0.81 | CA12 (0.41) | — | |
| SCHEMBL14037572 | 0.79 | — | — | |
| SCHEMBL13923678 | 0.75 | LMNA (0.39) | — | |
| SCHEMBL16158824 | 0.74 | — | — | |
| SCHEMBL17449863 | 0.74 | — | — | |
| SCHEMBL13923679 | 0.74 | — | — | |
| SCHEMBL5519860 | 0.74 | PAOX (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212503-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | UNIVERSITY OF CONNECTICUT (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212504-A1 | SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY | UNIVERSITY OF CONNECTICUT (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2018069764-A1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORPORATION (KR) | 2018-04-19 | — | — | WO | disclosed |
| US-20130040823-A1 | METHOD FOR THE SYNTHESIS OF A BIFUNCTIONAL COMPLEX | NUEVOLUTION A/S (DK) | 2013-02-14 | — | — | US | disclosed |
| US-8367065-B2 | Targeted polymeric prodrugs containing multifunctional linkers | ENZON PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8357670-B2 | Oligomeric compounds for the modulation of HIF-1A expression | ENZON PHARMACEUTICALS, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120322851-A1 | ORAL DELIVERY OF THERAPEUTICALLY EFFECTIVE LNA OLIGONUCLEOTIDES | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2012-12-20 | — | — | US | disclosed |
| US-20120122954-A1 | Antisense Oligomers Targeting PCSK9 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2012-05-17 | — | — | US | disclosed |
| US-20120115924-A1 | Micro-RNA Mediated Modulation of Colony Stimulating Factors | SANTARIS PHARMA A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| US-8110559-B2 | Hindered ester-based biodegradable linkers for oligonucleotide delivery | ENZON PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100330035-A1 | Pharmaceutical Compositions for Treatment of HCV Patients that are Poor-Responders to Interferon | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2010-12-30 | — | — | US | disclosed |
| US-20100234444-A1 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | ENZON PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7741309-B2 | Oligomeric compounds for the modulation of survivin expression | ENZON PHARMACEUTICALS | 2010-06-22 | — | — | US | disclosed |
| US-7737125-B2 | LNA antagonists targeting the androgen receptor | ENZON PHARAMACEUTICALS, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1706489-B1 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF BCL-2 | SANTARIS PHARMA AS (DK) | 2010-05-12 | — | — | EP | disclosed |
| US-20090318362-A1 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION | HANSEN JENS BO RODE | 2009-12-24 | — | — | US | disclosed |
| US-20090264353-A1 | Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease | SANTARIS PHARMA A/S | 2009-10-22 | — | — | US | disclosed |
| US-20090181916-A1 | LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR | SANTARIS PHARMA A/S (DK) | 2009-07-16 | — | — | US | disclosed |
| US-20090118213-A1 | RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-B100 EXPRESSION | SANTARIS PHARMA A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| US-20090005335-A1 | COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2009-01-01 | — | — | US | disclosed |